Identification of the ligands for KLRG1, an inhibitory receptor expressed on NK cells.

KLRG1 配体的鉴定,KLRG1 是 NK 细胞上表达的抑制性受体。

基本信息

  • 批准号:
    15590057
  • 负责人:
  • 金额:
    $ 2.37万
  • 依托单位:
  • 依托单位国家:
    日本
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
  • 财政年份:
    2003
  • 资助国家:
    日本
  • 起止时间:
    2003 至 2004
  • 项目状态:
    已结题

项目摘要

Bodies of the metazoan organisms are protected by the immune system. The immune system of vertebrates consists of acquired and innate immunity. Natural killer (NK) cells play pivotal roles in innate immunity especially against cancer cells and intracellular pathogens. NK cell recognition of targets involves NK cell receptors with opposing functions: inhibitory receptors and activating receptors. Balance of signals from these receptors decides activation of NK cells. Most of the known ligands for the inhibitory NK cell receptors are MHC class I molecules, which are considered as markers of self. However, NK cell recognition of targets is not solely depend on MHC class I. Indeed, NK cells express inhibitory receptors of which ligands are unidentified, which include KLRG1. KLRG1 is a lectin-like inhibitory receptor expressed on subsets of NK and T cells. Expression of KLRG1 is also regulated by infection. In the present study, our group identified three classical cadherins, which contribute to cell-cell adhesion through homotypic interaction, as ligands for KLRG1. We also showed that ligation of KLRG1 by E-cadherin inhibit NK cell ctyotoxocity. Because the classical cadherins that KLRG1 recognizes are distributed ubiquitously among the body, KLRG1 may contribute to the termination of immune response induced by infection. The notion that expression of E-cadherin is often lost or attenuated in malignant carcinoma raises a possibility that KLRG1-expressing NK cells may play a role in malignant tumor surveillance. The current study provides a new concept that cadherins contribute to regulation of immune response through recognition by KLRG1.
后生动物的身体受到免疫系统的保护。脊椎动物的免疫系统由后天免疫和先天免疫组成。自然杀伤(NK)细胞在先天免疫中起着关键作用,特别是针对癌细胞和细胞内病原体。NK细胞对靶标的识别涉及具有相反功能的NK细胞受体:抑制性受体和活化性受体。来自这些受体的信号的平衡决定NK细胞的激活。大多数已知的抑制性NK细胞受体的配体是MHC I类分子,其被认为是自身的标志物。然而,NK细胞对靶点的识别并不完全依赖于MHC I类。事实上,NK细胞表达抑制性受体,其配体未被鉴定,包括KLRG 1。KLRG 1是一种凝集素样抑制性受体,在NK和T细胞亚群上表达。KLRG 1的表达也受到感染的调节。在本研究中,我们的小组确定了三个经典的钙粘蛋白,这有助于细胞间粘附通过同型相互作用,作为配体KLRG 1。我们还发现,通过E-钙粘蛋白连接KLRG 1可以抑制NK细胞的细胞毒性。由于KLRG 1识别的经典钙粘蛋白广泛分布于机体,因此KLRG 1可能有助于终止感染诱导的免疫应答。在恶性肿瘤中E-钙粘蛋白的表达经常丢失或减弱的概念提出了表达KLRG 1的NK细胞可能在恶性肿瘤监视中发挥作用的可能性。目前的研究提供了一个新的概念,即钙粘蛋白通过识别KLRG 1来调节免疫反应。

项目成果

期刊论文数量(44)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity.
杀伤细胞凝集素样受体G1结合经典钙粘蛋白家族的三个成员,以抑制NK细胞细胞毒性。
  • DOI:
    10.1084/jem.20051986
  • 发表时间:
    2006-02-20
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Ito M;Maruyama T;Saito N;Koganei S;Yamamoto K;Matsumoto N
  • 通讯作者:
    Matsumoto N
B-la cell origin of the murine B lymphoma line BCLIcharacterized by surface markers and bacterial reactivity of its surface IgM
鼠 B 淋巴瘤系 BCLI 的 B-la 细胞起源,其特征在于其表面 IgM 的表面标记和细菌反应性
  • DOI:
  • 发表时间:
    2005
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kogamei S.;Ito M.;Yamamoto K.;Matsumoto N.
  • 通讯作者:
    Matsumoto N.
Annual Review 免疫2007
免疫学年度回顾 2007
  • DOI:
  • 发表时间:
    2007
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Saito M;Minegishi Y;Nonoyama S;and Karasuyama H.;鳥山 一
  • 通讯作者:
    鳥山 一
Tajima K., Matsumoto N., Ohmori K., Wada H., Ito M., Suzuki K., Yamamoto K.: "Augmentation of NK cell-mediated cytotoxicity to tumor cells by inhibitory NK cell receptor blockers."International Immunology. 16. 385-393 (2004)
Tajima K.、Matsumoto N.、Ohmori K.、Wada H.、Ito M.、Suzuki K.、Yamamoto K.:“通过抑制性 NK 细胞受体阻断剂增强 NK 细胞介导的对肿瘤细胞的细胞毒性。”国际免疫学。
  • DOI:
  • 发表时间:
  • 期刊:
  • 影响因子:
    0
  • 作者:
  • 通讯作者:
A species-specific determinant of β_2-microglobulin required for Ly49A recognition of its MHC class I ligand
Ly49A 识别其 MHC I 类配体所需的 β_2-微球蛋白的物种特异性决定簇
  • DOI:
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Mitsuki M.;Matsumoto N.;Yamamoto K.
  • 通讯作者:
    Yamamoto K.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MATSUMOTO Naoki其他文献

MATSUMOTO Naoki的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MATSUMOTO Naoki', 18)}}的其他基金

Development of efficient graph enumeration algorithms using graph generating theorems
使用图生成定理开发高效的图枚举算法
  • 批准号:
    19K14583
  • 财政年份:
    2019
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The relationship between landiolol and BCHE in the pediatric patients with congenital heart disease.
兰地洛尔与BCHE在儿科先天性心脏病患者中的关系
  • 批准号:
    26861256
  • 财政年份:
    2014
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
The elucidation of myocardial protection effect and the development of myocardial protective strategy by beta-blocker, landiolol, in children.
β受体阻滞剂兰地洛尔对儿童心肌保护作用的阐明及心肌保护策略的制定
  • 批准号:
    24890292
  • 财政年份:
    2012
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Function of the inhibitory receptor KLRG1 in innate and acquiredimmunity
抑制性受体 KLRG1 在先天性和获得性免疫中的功能
  • 批准号:
    19590059
  • 财政年份:
    2007
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Efficacy of slow-rate repetitive transcranial magnetic stimulation in the treatment of depression.
慢速重复经颅磁刺激治疗抑郁症的疗效。
  • 批准号:
    17591231
  • 财政年份:
    2005
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
STUDY OF GLOBAL CONVERGENCE OF ADAPTIVE IIR FILTER BASED ON PSEUDO LINEAR REGRESSION METHOD
基于伪线性回归方法的自适应IIR滤波器全局收敛性研究
  • 批准号:
    09650489
  • 财政年份:
    1997
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)

相似海外基金

Dissecting the heterogeniety of human tissue-resident memory T cells
剖析人体组织驻留记忆 T 细胞的异质性
  • 批准号:
    DE240101101
  • 财政年份:
    2024
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Discovery Early Career Researcher Award
Integrating subcellular multi-omics to identify druggable metabolic markers of latent HIV infection in CD4 T-cells
整合亚细胞多组学来识别 CD4 T 细胞中潜在 HIV 感染的可药物代谢标志物
  • 批准号:
    MR/Y013093/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Research Grant
Advancing entirely virus-free CRISPR CAR T cells to clinic- Are they as good as lentiviral CAR?
将完全无病毒的CRISPR CAR T细胞推向临床——它们和慢病毒CAR一样好吗?
  • 批准号:
    MR/Y503496/1
  • 财政年份:
    2024
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Research Grant
Generation of intra-tumoral stem-like tissue-resident memory CD8+ T cells, as a novel immunotherapeutic strategy against cancer
生成肿瘤内干细胞样组织驻留记忆 CD8 T 细胞,作为一种新型的癌症免疫治疗策略
  • 批准号:
    24K18475
  • 财政年份:
    2024
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Delineating the developmental requirements for stem-like T cells
描述干样 T 细胞的发育要求
  • 批准号:
    DE240100827
  • 财政年份:
    2024
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Discovery Early Career Researcher Award
How do unconventional T cells die?
非常规T细胞如何死亡?
  • 批准号:
    DP240101173
  • 财政年份:
    2024
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Discovery Projects
A triptych of structural dynamics in the advancement of global health (in)equity in CAR-T cells and gene therapies
CAR-T 细胞和基因疗法推动全球健康(不)公平的结构动力学三联体
  • 批准号:
    24K15887
  • 财政年份:
    2024
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Exploring the potential of type-1 regulatory T cells in resolution and recovery from intestinal inflammation
探索 1 型调节性 T 细胞在解决和恢复肠道炎症方面的潜力
  • 批准号:
    478356
  • 财政年份:
    2023
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Operating Grants
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Operating Grants
Therapeutic strategies for sepsis-associated mental disorders focusing on T cells and neurogenesis in the brain.
脓毒症相关精神障碍的治疗策略重点关注大脑中的 T 细胞和神经发生。
  • 批准号:
    23K08459
  • 财政年份:
    2023
  • 资助金额:
    $ 2.37万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了